A PYMNTS Company

US: $10.4B pharma merger confirmed after months of speculation

By  |  August 26, 2013

Following months of reported rumors that biotechnology company Amgen was looing to acquire Onyx Pharmaceuticals, the two companies have confirmed plans of the transaction. Reports say the deal was made for about $10.4 billion $9.7 billion in cash, at $125 per share. The parties expect to close the deal by the year’s fourth quarter. This will be the second move by Amgen to acquire Onyx Pharma; Oynx turned down a previous offer made earlier this year for $120 a share, a deal Oynx said undervalued the company.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Full Content: Yahoo Finance

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.